Elyse Bianchet

Ms. Elyse Bianchet

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ASAdams L. Sibley
Adams L. Sibley
RBRobin Baker
Robin Baker
XLXimena A. Levander
Ximena A. Levander
ARAlex Rains
Alex Rains
SWSuzan M. Walters
Suzan M. Walters
VGVivian F. Go
Vivian F. Go

27 August 2024 in Viruses
Verified
Journal Article
Open access
PDF file
EREric Romo
Eric Romo
EBElyse Bianchet
Elyse Bianchet
PDPatrick Dowd
Patrick Dowd
KMKathleen M. Mazor
Kathleen M. Mazor
TSThomas J Stopka
Thomas J Stopka
PFPeter D. Friedmann
Peter D. Friedmann
The ongoing hepatitis C virus (HCV) epidemic in the United States disproportionately affects rural people who inject drugs (PWID). This study explores the HCV risk environment in rural northern New England by examining PWID experiences and perceptions of HCV and injection equipment-sharing practices. We performed a thematic analysis on semi-structured interviews conducted with 21 adults with a history of injection drug use from rural New Hampshire, Vermont, and Massachusetts between April 2018 and August 2019. Salient themes included: (1) limited and varied access to sterile syringe sources; (2) syringe scarcity contributing to the use of informal syringe sources (e.g., secondary syringe exchange or syringe sellers who purchased syringes from out-of-state pharmacies); (3) syringe scarcity contributing to syringe sharing; (4) linkages among decisions about syringe sharing and perceptions of HCV risk, HCV status, and interpersonal trust; and (5) confusion and misconceptions about HCV, including difficulty learning one’s HCV status, inadequate HCV education, and misconceptions regarding HCV transmission and treatment. Efforts to prevent and eliminate HCV among rural PWID should expand syringe access, increase awareness of HCV as a serious but preventable risk, and acknowledge social connections as potential influences on syringe access and syringe-sharing decisions.

30 August 2024 in Viruses
Verified
Journal Article
Open access
PDF file
EBElyse Bianchet
Elyse Bianchet
DGDavid de Gijsel
David de Gijsel
LTLizbeth Del Toro-Mejias
Lizbeth Del Toro-Mejias
TSThomas J Stopka
Thomas J Stopka
RHRandall Hoskinson
Randall Hoskinson
PFPeter D. Friedmann
Peter D. Friedmann
Hepatitis C virus (HCV) disproportionately affects people who inject drugs (PWID). Although HCV has become universally curable since the arrival of direct-acting antivirals, barriers exist to facilitating care and cure in this historically hard-to-reach population, including limited testing and healthcare services and healthcare stigma, issues that are compounded in rural areas. Telehealth is effective in increasing access to HCV care and cure, but innovative approaches of testing and care are required to fully address the need among rural PWID, which led to our study examining a mobile telehealth model for treating HCV. In this commentary, we discuss lessons learned delivering telehealth on a mobile unit, important factors for consideration when designing a mobile intervention, and we suggest an ideal model to increase access to HCV testing and treatment and other services for rural PWID.